ID
11320
Description
Study documentation part: Screening This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.
Keywords
Versions (1)
- 6/30/15 6/30/15 -
Uploaded on
June 30, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening
Description
Demographics
Alias
- UMLS CUI-1
- C1704791
Description
Date of birth
Data type
date
Alias
- UMLS CUI-1
- C0421451
Description
Gender at birth
Data type
text
Alias
- UMLS CUI-1
- C0079399
Description
Race
Data type
text
Alias
- UMLS CUI-1
- C0034510
Description
Other race
Data type
text
Alias
- UMLS CUI-1
- C0034510
Description
Ethnicity (For United states only)
Data type
text
Description
Informed consent
Alias
- UMLS CUI-1
- C0514044
- UMLS CUI-2
- C0805443
Description
Was informed consent obtained prior to any study related procedures?
Data type
boolean
Alias
- UMLS CUI-1
- C0021430
Description
If you chose above the option "Yes", please enter the date subject or legally authorized representative signed informed consent.
Data type
date
Alias
- UMLS CUI-1
- C0011008
Description
Eligibility criteria
Alias
- UMLS CUI-1
- C0332307
- UMLS CUI-2
- C0030705
- UMLS CUI-3
- C1513905
- UMLS CUI-4
- C1516637
Description
Did the subject fail any eligibility criteria?
Data type
boolean
Alias
- UMLS CUI-1
- C0332307
- UMLS CUI-2
- C0030705
- UMLS CUI-3
- C1513905
- UMLS CUI-4
- C1516637
Description
If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s)
Data type
text
Alias
- UMLS CUI-1
- C0231175
- UMLS CUI-2
- C1516637
- UMLS CUI-3
- C1512693
- UMLS CUI-4
- C0680251
Description
Pre-randomization status
Alias
- UMLS CUI-1
- C0034656
- UMLS CUI-2
- C0449438
Description
Will the subject be randomized?
Data type
boolean
Alias
- UMLS CUI-1
- C0034656
Description
If you chose "No" above, please indicate primary reason for not being randomized?
Data type
text
Alias
- UMLS CUI-1
- C0034656
Description
Please specify if you chose "Subject withdrew consent", "Poor/ Non-Compliance", "Subject no longer meets study criteria" or "Other"
Data type
text
Alias
- UMLS CUI-1
- C0392360
Description
Please specify the date of last contact, if you chose "Lost to follow-up".
Data type
date
Alias
- UMLS CUI-1
- C0011008
Description
Treatment assignment
Alias
- UMLS CUI-1
- C1522541
Similar models
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening
C0545082 (UMLS CUI-2)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
C1516637 (UMLS CUI-2)
C1512693 (UMLS CUI-3)
C0680251 (UMLS CUI-4)
C0449438 (UMLS CUI-2)
C0027365 (UMLS CUI-2)